The impact of perioperative packed red blood cell transfusion on survival in epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 23, Issue 9, 2013, Pages 1612-1619

  Warner, Lindsay L Morgenstern ^a   Dowdy, Sean C ^b   Martin, Janice R ^b   Lemens, Maureen A ^b   McGree, Michaela E ^b   Weaver, Amy L ^b   Podratz, Karl C ^b   Bakkum Gamez, Jamie N ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Disease free survival; Ovarian cancer; Overall survival; Perioperative red blood cell transfusion

Indexed keywords

ADULT; ARTICLE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OPERATION DURATION; OPERATIVE BLOOD LOSS; OVARY CARCINOMA; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK FACTOR; SPLENECTOMY; SURGICAL MORTALITY; TOTAL QUALITY MANAGEMENT;

AGED; BLOOD LOSS, SURGICAL; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERIOPERATIVE PERIOD; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84888316904     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/01.IGC.0000436089.03581.6b     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Zivanovic O, Eisenhauer EL, Zhou Q, et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2008; 108: 287-292.
3. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009; 114: 26-31.
4. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006; 107: 77-85.
5. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006; 107: 77-85.
6. Ozols RF. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J Clin Oncol. 2003; 21: 2451-2453.
7. Lee M, Kim SW, Paek J, et al. Comparisons of surgical outcomes, complications, and costs between laparotomy and laparoscopy in early-stage ovarian cancer. Int J Gynecol Cancer. 2011; 21: 251-256.
8. McCann CK, Growdon WB, Munro EG, et al. Prognostic significance of splenectomy as part of initial cytoreductive surgery in ovarian cancer. Ann Surg Oncol. 2011; 18: 2912-2918.
9. Kim HS, Kim EN, Jeong SY, et al. Comparison of the efficacy of low anterior resection with primary anastomosis and Hartmann's procedure in advanced primary or recurrent epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2011; 156: 194-198.
10. Bakkum-Gamez JN, Langstraat CL, Martin JR, et al. Incidence of and risk factors for postoperative ileus in women undergoing primary staging and debulking for epithelial ovarian carcinoma. Gynecol Oncol. 2012; 125: 614-620.
11. De Oliveira GS, Schink JC, Buoy C, et al. The association between allogeneic perioperative blood transfusion on tumour recurrence and survival in patients with advanced ovarian cancer. Transfus Med. 2012; 22: 97-103.
12. Lee M, Kim SW, Paek J, et al. Comparisons of surgical outcomes, complications, and costs between laparotomy and laparoscopy in early-stage ovarian cancer. Int J Gynecol Cancer. 2011; 21: 251-256.
13. Amato AC, Pescatori M. Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors. Dis Colon Rectum. 1998; 41: 570-585.
14. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006; 1:CD005033.
15. Busch OR, Hop WC, Hoynck van Papendrecht MA, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med. 1993; 328: 1372-1376.
16. Pacelli F, Rosa F, Marrelli D, et al. Do perioperative blood transfusions influence prognosis of gastric cancer patients? Analysis of 927 patients and interactions with splenectomy. Ann Surg Oncol. 2011; 18: 1615-1623.
17. Weitz J, D'Angelica M, Gonen M, et al. Interaction of splenectomy and perioperative blood transfusions on prognosis of patients with proximal gastric and gastroesophageal junction cancer. J Clin Oncol. 2003; 21: 4597-4603.
18. Choi JH, Chung HC, Yoo NC, et al. Perioperative blood transfusions and prognosis in patients with curatively resected locally advanced gastric cancer. Oncology. 1995; 52: 170-175.
19. Gilliss BM, Looney MR. Experimental models of transfusion-related acute lung injury. Transfus Med Rev. 2011; 25: 1-11.
20. Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007; 116: 2544-2552.
21. Scott B, Seifert F, Grimson R. Blood transfusion is associated with increased resource utilisation, morbidity and mortality in cardiac surgery. Ann Card Anaesth. 2008; 11: 15-19.
22. Hall BL, Hamilton BH, Richards K, et al. Does surgical quality improve in the American College of Surgeons National Surgical Quality Improvement Program: an evaluation of all participating hospitals. Ann Surg. 2009; 250: 363-376.
23. Khuri SF, Daley J, Henderson WG. The comparative assessment and improvement of quality of surgical care in the Department of Veterans Affairs. Arch Surg. 2002; 137: 20-27.
24. Aletti GD, Dowdy SC, Podratz KC, et al. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007; 197:676.
25. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17: 2265-2281.
26. Obermair A, Petru E, Windbichler G, et al. Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep. 2000; 7: 639-644.
27. Upile T, JerjesW, Mahil J, et al. An explanation for theworsened prognosis in some cancer patients of perioperative transfusion: the time-dependent release of biologically active growth factors from stored blood products. Eur Arch Otorhinolaryngol. 2011; 268: 1789-1794.
28. Upile T, Jerjes W, Sandison A, et al. The direct effects of stored blood products may worsen prognosis of cancer patients; shall we transfuse or not? An explanation of the adverse oncological consequences of blood product transfusion with a testable hypothesis driven experimental research protocol. Med Hypotheses. 2008; 71: 489-492.
29. Martin-Loeches M, Ortí RM, Asins E, et al. The prognostic implications of anaemia in the outcome of patients with early stages of uterine cervix carcinoma. Arch Gynecol Obstet. 2003; 267: 121-125.
30. Spirtos NM, Westby CM, Averette HE, et al. Blood transfusion and the risk of recurrence in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J Clin Oncol. 2002; 25: 398-403.
31. Monk B, Tewari K, Gamboa-Vujicic G, et al. Does perioperative blood transfusion affect survival in patients with cervical cancer treated with radical hysterectomy? Obstet Gynecol. 1995; 58: 343-348.
32. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008; 108: 317-325.
33. Gupta S, Singh PK, Bisth SS, et al. Role of recombinant human erythropoietin in patients of advanced cervical cancer treated "by chemoradiotherapy". Cancer Biol Ther. 2009; 8: 13-17.
34. Blohmer JU, Paepke S, Sehouli J, et al. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. J Clin Oncol. 2011; 29: 3791-3797.
35. Cantrell LA, Westin SN, Van Le L. The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival. Cancer. 2011; 117: 1220-1226.
36. Berséus O, Boman K, Nessen SC, et al. Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma. Transfusion. 2013; 53:114SY123S.
37. Neal MD, Raval JS, Triulzi DJ, et al. Innate immune activation after transfusion of stored red blood cells. Transfus Med Rev. 2013; 27: 113-118.
38. Odent-Malaure H, Quainon F, Ruyer-Dumontier P, et al. Transfusion related acute lung injury (TRALI) caused by red blood cell transfusion involving residual plasma anti-HLA antibodies: a report on two cases and general considerations. Clin Dev Immunol. 2005; 12: 243-248.